Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: Results from the PLATelet inhibition and patient outcomes (PLATO) study

Clinical Chemistry

Volumn 59, Issue 9, 2013, Pages 1369-1375

  Åkerblom, Axel ^a   Wallentin, Lars ^a   Larsson, Anders ^a   Siegbahn, Agneta ^a   Becker, Richard C ^b   Budaj, Andrzej ^c   Himmelmann, Anders ^d   Horrow, Jay ^e   Husted, Steen ^f   Storey, Robert F ^g   Åsenblad, Nils ^a   James, Stefan K ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c GROCHOWSKI HOSPITAL   (Poland)

^d ASTRAZENECA R AND D   (Sweden)

^e ASTRAZENECA   (United Kingdom)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATININE; CYSTATIN C;

ACUTE CORONARY SYNDROME; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BLAND ALTMAN METHOD; CARDIOVASCULAR MORTALITY; CLINICAL TRIAL (TOPIC); CONFIDENCE INTERVAL; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; INTEGRATED DISCRIMINATION IMPROVEMENT; KIDNEY FUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PARAMETERS; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT; STATISTICAL ANALYSIS;

ACUTE CORONARY SYNDROME; CREATININE; CYSTATIN C; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MODELS, STATISTICAL; PROGNOSIS; RISK FACTORS;

EID: 84883368105     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.200709     Document Type: Article

References (22)

1. Grubb AO. Cystatin C: properties and use as diagnostic marker. Adv Clin Chem 2000;35:63-99.
2. Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002;48:699 -707.
3. Chew JS, Saleem M, Florkowski CM, George PM. Cystatin C: a paradigm of evidence based laboratory medicine. Clin Biochem Rev 2008;29:47-62.
4. Grubb A, Lofberg H. Human gamma-trace, a basic microprotein: amino acid sequence and presence in the adenohypophysis. Proc Natl Acad Sci U S A 1982;79:3024 -7.
5. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004;65:1416 -21.
6. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992;38:1933-53.
7. Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem 2009;55:1932- 43.
8. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004;110:2342- 8.
9. Akerblom A, Wallentin L, Siegbahn A, Becker RC, Budaj A, Buck K, et al. Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the platelet inhibition and patient outcomes study. Clin Chem 2012;58:190 -9.
10. Windhausen F, Hirsch A, Fischer J, van der Zee PM, Sanders GT, van Straalen JP, et al. Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T. Clin Chem 2009;55:1118-25.
11. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604 -12.
12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
14. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004;291:2727-33.
15. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20 -9.
16. Shlipak MG, Weekley CC, Li Y, Hansson LO, Larsson A, Whooley M. Comparison of cardiovascular prognosis by 3 serum cystatin C methods in the heart and soul study. Clin Chem 2011;57:737-45.
17. Gentian. Cystatin C immunoassay. http://www.gentian.no/public/index.php? contents-cysc (Accessed May 2013).
18. James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the platelet inhibition and patient outcomes trial. Am Heart J 2009;157: 599-605.
19. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
20. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
21. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 25:157-72; discussion 207-12.
22. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology. Eur Heart J 2011; 32:2999 -3054.